A preclinical systematic review and meta-analysis of astragaloside IV for myocardial ischemia/reperfusion injury

Zheng, Qun and Zhu, JiaZhen and Bao, XiaoYi and Zhu, PengChong and Tong, Qiang and Huang, YueYue and Zhang, QiHao and Zhang, KeJian and Zheng, GuoQing and Wang, Yan

Frontiers in Physiology (2018) 9:

DOI: 10.3389/fphys.2018.00795

Abstract

Astragaloside IV (AS-IV), the major pharmacological extract from Astragalus membranaceus Bunge, possesses a variety of biological activities in the cardiovascular systems. Here, we aimed to evaluate preclinical evidence and possible mechanism of AS-IV for animal models of myocardial ischemia/reperfusion (I/R) injury. Studies of AS-IV in animal models with myocardial I/R injury were identified from 6 databases from inception to May, 2018. The methodological quality was assessed by using CAMARADES 10-item checklist. All the data were analyzed using Rev-Man 5.3 software. As a result, 22 studies with 484 animals were identified. The quality score of studies ranged from 3 to 6 points. Meta-analyses showed AS-IV can significantly decrease the myocardial infarct size and left ventricular ejection fraction, and increase shortening fraction compared with control group (P\textless0.01). Significant decreasing of cardiac enzymes and cardiac troponin and increasing of decline degree in ST-segment were reported in one study each (P\textless0.05). Additionally, the possible mechanisms of AS-IV for myocardial I/R injury are promoting angiogenesis, improving the circulation, antioxidant, anti-inflammatory and anti-apoptosis. Thus, AS-IV is a potential cardioprotective candidate for further clinical trials of myocardial infarction.

Citation

Zheng, Q., Zhu, J. Z., Bao, X. Y., Zhu, P. C., Tong, Q., Huang, Y. Y., Zhang, Q. H., Zhang, K. J., Zheng, G. Q., & Wang, Y. (2018). A preclinical systematic review and meta-analysis of astragaloside IV for myocardial ischemia/reperfusion injury. Frontiers in Physiology, 9(July). https://doi.org/10.3389/fphys.2018.00795 angiogenesis, apoptosis, meta-analysis, animal models, systematic reviews, plants, medicinal plants, plant extracts, antiinflammatory properties, antioxidant properties, enzymes, saponins, Animal and in vitro Models for Pharmaceuticals [VV450], Animal Models of Human Diseases [VV400], myocardial infarction, drug plants, medicinal herbs, officinal plants, Non-food/Non-feed Plant Products [SS200], anti-inflammatory properties, anti-oxidant properties, Astragalus propinquus, cardiac muscle, heart attack, heart muscle, ischaemic heart disease, myocardial ischaemia, myocardial ischemia, myocardium, troponins

Keywords

• angiogenesis
• apoptosis
• meta-analysis
• animal models
• systematic reviews
• plants
• medicinal plants
• plant extracts
• antiinflammatory properties
• antioxidant properties
• enzymes
• saponins
• Animal and in vitro Models for Pharmaceuticals [VV450]
• Animal Models of Human Diseases [VV400]
• myocardial infarction
• drug plants
• medicinal herbs
• officinal plants
• Non-food/Non-feed Plant Products [SS200]
• anti-inflammatory properties
• anti-oxidant properties
• Astragalus propinquus
• cardiac muscle
• heart attack
• heart muscle
• ischaemic heart disease
• myocardial ischaemia
• myocardial ischemia
• myocardium
• troponins